Opportunities
Search

The Housing Policy Research Grant Notice of Funding Opportunity provides competitive awards to eligible applicants, including institutions of higher education, nonprofit, and for-profit institutions. Awards made through this NOFO will fund quality research projects that: (1) contribute to knowledge about housing policy in the United States; and (2) generate actionable insights and evidence that can applied by policymakers and communities in the short-term.

This NOFO seeks proposals for rigorous applied research and evaluative studies on the forensic science system. The field of forensic science is changing, particularly as technological advancements improve the criminal justice system’s ability to use forensic evidence more effectively and efficiently. Research is needed to better understand the impact of forensic science on the criminal justice system and law enforcement operations. With this NOFO, NIJ requests applications in three topic areas: • The impact of forensic science on the criminal justice system and law enforcement operations, such as improving investigative clearance rates, increasing law enforcement effectiveness, and reducing crime lab backlogs. • Evaluations of the implementation of new and innovative forensic science methods and their impact on strengthening courtroom admissibility and evidentiary reliability. • Developing the forensic science workforce.

The purpose of this notice of funding opportunity (NOFO) is to support the establishment or continuation of longitudinal infant cohorts to determine and compare how initial and repeated natural influenza infections and/or influenza vaccinations shape infant and childhood immunity to future influenza exposures. The goal of this research is to understand how these exposures influence immune responses to subsequent influenza infections and/or vaccines and provide key information to facilitate design of durable, broadly protective influenza vaccines.

This NOFO seeks applications for rigorous applied research on the intersection of drug crimes and firearms to inform the development of evidence-based tools, practices, and policies for state, tribal, and local law enforcement and other criminal justice stakeholders that address drug trafficking, drug markets, and drug-related violence. With this FY25 NOFO, NIJ seeks applications in four topic areas: (1) Pattern Identification; (2) Interdiction & Disruption Strategies; (3) Prosecution; and (4) Drug Market Dynamics.

Background The FDA Oncology Center of Excellence (OCE) aims to advance the development and regulation of oncology products for patients with cancer. The Pediatric Oncology Program and Rare Cancers Program were established to facilitate and expedite drug development for pediatric and other rare cancers. OCE’s Project Catalyst connects scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation, which is particularly important to address the challenges related to product development for ultra-rare cancers. In collaboration with the National Institutes of Health (NIH) and the OCE, the Foundation for the National Institutes of Health (FNIH) recently launched the design phase of the Ultra-Rare Cancer Treatment Advancement Program (ULTRA), a new public-private partnership dedicated to accelerating the development of innovative ultra-rare cancer treatments.  For the purposes of this NOFO, the FDA OCE refers to cancers with an approximate annual incidence in the U.S. of 300 to 400 people or less as ultra-rare (a more stringent criterion compared to the threshold for a rare disease specified in the Orphan Drug Act based on a U.S. prevalence of

This NOFO will support research and evaluation of emerging technology implementation and impact for law enforcement purposes. Topics include policies, trainings, operational and staffing issues; communications strategies associated with technology implementation; and impacts of technology implementation and use on public safety and agency budgets. NIJ encourages researchers and practitioners to partner or build on existing researcher-practitioner partnerships to guide the law enforcement community on the best ways to implement technology to solve contemporary problems in policing. Applying for this funding opportunity involves a two-stage process that begins with submission of a concept paper. Based on the merits of the concept paper, NIJ may request that the applicant submit a full proposal. Applicants should not submit a full proposal unless invited. For information on the concept paper format, please see the General Purpose of the Funding section of this NOFO.

The goal of this NOFO is to gather unique information not collected by other federal programs to gain a better understanding of the resources (e.g., services, supports) and opportunities (e.g., education, employment, housing, social participation) needed to reduce morbidity, mortality, and economic impacts and improve other long-term outcomes for people with autism or Fragile X Syndrome (FXS) across the lifespan. CDC proposes to implement three components in this NOFO.Component A: Survey to Promote Resources and Opportunities for aUtistic Teens and young adults (SPROUT) will utilize cohorts from the Study to Explore Early Development (SEED) Phases 1-3 (collected from 2007-2020), which were case-control studies of autism in children 2-5 years of age. Participants will range from about 10-25 years of age when this NOFO is awarded. SPROUT will be comprised of caregiver and self-report surveys intended to offer unique information on (1) service and support needs and the impact of co-occurring conditions on autistic people and their families and (2) the educational, transitional, social, and/or vocational needs and experiences of autistic adolescents and young adults. Information from these surveys will be used to improve the health and wellbeing of autistic people and their families. These activities are intended to provide data to inform ways to lessen individual, familial, and societal costs associated with autism, reduce morbidity and mortality, and improve health and well-being.Component B: Focus on Advancing Support and Transition with the Fragile X Online Registry With Ac...

This Notice of Funding Opportunity (NOFO) seeks applications to optimize instrumentation and device technologies for recording and modulation of neural cells and circuits, to address major challenges and to enable transformative understanding of dynamic signaling in the central nervous system. It is expected that the proposed technologies and approaches have previously demonstrated their transformative potential through initial proof-of-concept testing, and are ready for accelerated refinement through iterative engineering and end-user feedback, appropriate for a path towards sustainable dissemination and user-friendly incorporation into routine neuroscience research. Applications may propose development of instrumentation hardware and/or devices and associated software. Approaches may utilize any modality such as optical, electrical, magnetic, or acoustic recording/manipulation, to target neuronal electrical signals or other forms of neural activity, including intracellular signaling and engagement of non-neuronal cells in circuit function. This NOFO is a re-issue of RFA-NS-21-027, but unlike the previous NOFO the focus is narrowed to technologies associated with recording/manipulation instrumentation and devices, and excludes projects primarily focused on development of molecular reagents. Potential applicants primarily optimizing molecular constructs should consider RFA-MH-22-245 (or its reissue), BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits (UM1 Clinical Trial Not Allowed). For projects at an earli...

The purpose of this NOFO is to improved awareness and knowledge of alpha-gal syndrome (AGS) in the United States. AGS is an emerging condition and is not nationally notifiable. This NOFO seeks to improve AGS surveillance, patient care, and public awareness and understanding. The NOFO strategies are to 1) SHARE - Formation of a network of AGS professionals to disseminate latest knowledge of AGS among stakeholders, including public health agencies, academic researchers, and advocacy groups, in order to improve patient care for AGS and the public health response. 2) EDUCATE - Create AGS communications targeted at the general public, AGS patients, or persons at higher risk for tick encounters (outdoor enthusiasts, dog owners, outdoor workers, etc.). Create communications targeted at healthcare providers including educational resources and training. 3) TRACK - Conduct active or enhances public health surveillance for AGS. This strategy could involve patient populations or geographical locations with limited access to specialized healthcare provider care.

The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required.

The purpose of this proposed Notice of Funding Announcement (NOFO) is to support development of biomarkers or clinical outcomes derived from digital health technology (DHT) for use in clinical trials for remote monitoring as primary or secondary endpoints. To improve clinical impact, increase statistical feasibility, and promote standardization, applicants will be expected to develop and test the digitally derived assessments in populations from at least three different diseases or conditions. Partnerships with non-profit patient advocacy organizations will be required.

This notice of funding opportunity (NOFO) supports research, implementation science, and public health evaluations to inform best practices for preventing and responding to infectious disease threats in Kenya, while strengthening local research capacity.The award recipient will conduct research, implementation science, and public health evaluations through the Kenya Medical Research Institute (KEMRI) and focus on four required priority areas:Influenza and other respiratory pathogens: Activities include surveilling high-risk groups; monitoring for human and avian influenza and other pathogens; and evaluating efficacy and use of vaccines and other treatments. Outcomes include increasing understanding of disease burden and improving vaccination strategies.Vaccine-preventable diseases: Research will assess disease burden, vaccine effectiveness, and sociocultural factors influencing immunization. Outcomes include increasing vaccine uptake and strengthening immunization systems.Drug-resistant infections: Activities include monitoring antimicrobial resistance (AMR) trends, applying novel diagnostics, and identifying drivers of resistance. Outcomes include improving mitigation strategies and global AMR preparedness.Global and emerging health threats: Research will address malaria, HIV, tuberculosis, schistosomiasis, and emerging infections. Outcomes include improving understanding of disease dynamics, intervention effectiveness, and cross-border risks.The recipient will also conduct research coordination and administration activities to manage and oversee U.S. government–funded pub...

The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $3,000,000 for Year 1, subject to the availability of funds.The purpose of this NOFO is to reduce TB-related morbidity and mortality in India, the Philippines, and Vietnam by strengthening:• TB case finding, including linked activities such as screening, testing, and diagnostic evaluation.• TB prevention, including TB preventive treatment (TPT).• TB treatment, including linkage and improved treatment regimens, as appropriate.• Surveillance, through adopting, evaluating, and expanding innovative approaches.Activities implemented will focus on:• Expanding and improving diagnosis of TB infection and TB disease, including early and asymptomatic TB as well as drug-resistant or multidrug-resistant TB. This will be done by using and evaluating innovative screening and diagnostic methods and scaling up evidence-based approaches. • Improving TPT outcomes for all individuals at high risk of developing TB disease and improving TB treatment outcomes of individuals with TB disease, including those with drug-resistant or multidrug-resistant TB. This will be done by using new, shorter, and better-tolerated treatment regimens.• Strengthening TB surveillance for data-driven decision making, program planning, and public health action.Asia carries the highest burden of TB and drug-resistant or multidrug-resistant TB globally. This NOFO will focus on activities in India, the Philippines, and Vietnam because they are three of the top four countries contributing to the TB burden in the U....

The National Institute for Occupational Safety and Health (NIOSH) supports research projects that address: (1) physical and mental health conditions related to the September 11, 2001, terrorist attacks; (2) diagnosing conditions for which there has been diagnostic uncertainty; and (3) treating conditions for which there has been treatment uncertainty. Conditions may have emerged since the treatment program began or since the WTC Health Program was established. This announcement solicits meritorious and scientifically rigorous applications that will: 1) improve diagnosis and treatment activities of the WTC Health Program; 2) expand knowledge about health effects related to the September 11, 2001, terrorist attacks; 3) answer critical questions about WTC-related physical and mental health conditions; and 4) apply lessons learned to improve response to future disasters. Potential projects may include, but are not limited to: (a) Screening research to evaluate current methods or facilitate the development of new or improved methods to detect disorders or health conditions; (b) Diagnostic research to evaluate current methods or facilitate the development of new or improved methods to identify diseases, disorders, or conditions; (c) Treatment research to evaluate or identify improved treatment interventions or methods, or to promote development of new or novel approaches; (d) Prevention research to identify or evaluate methods and interventions that prevent or mitigate the development or recurrence of diseases or disorders; (e) Quality of life research to identify, develop, or ev...

NOAA/NMFS is soliciting competitive proposals for grants and cooperative agreements for projects that will support NOAA’s mission for stewardship of living marine resources and the sustainable management of U.S. commercial longline fisheries. Projects will ensure data pipelines are in place to inform the sustainable management of U.S. commercial fisheries that interact with endangered species as they migrate throughout the Pacific — a problem that has led to fishery closures when annual interaction limits are reached. Through these efforts, NOAA will strengthen the competitiveness of U.S. commercial longline fisheries, creating a more level playing field for American fishermen, while reinforcing U.S. leadership in marine resource management. Projects must benefit aggregations of endangered marine turtles that have documented linkages to the Pacific Islands Region (PIR), are impacted by PIR federally managed commercial fisheries, and address NOAA’s Endangered Species Act (ESA) recovery obligations. For the Fiscal Year (FY) 2026 funding competition, we are soliciting projects that: 1) monitor and implement protection measures to conserve western Pacific leatherback sea turtles occurring in the Coral Triangle region (Indonesia, Malaysia, the Philippines, Papua New Guinea, or Solomon Islands); 2) monitor and implement protection measures to conserve North Pacific loggerhead sea turtles in Japan; and 3) progress conservation momentum and build capacity for research, monitoring and protection of endangered marine turtle populations in order to benefit U.S. trust resources that oc...

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish a Pharmacokinetics Resource Laboratory (PK Laboratory) to support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratory will organize biospecimen collections and provide subsequent analyses of pharmacokinetic endpoints, drug-drug interactions, cytochrome P450 (CYP) interactions, pharmacodynamics, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratory is to advance the clinical development of NCI IND agents by providing a comprehensive understanding of pharmacokinetic behavior of these agents under study in ETCTN trials. The ETCTN PK Laboratory will engage physicians, clinical pharmacologists, nurses, and scientists who have appropriate expertise in pharmacokinetic studies for early drug development and translational research. This NOFO seeks U24 applications from multidisciplinary institutions/organizations to conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to IND applications in the NCI Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish Lead Academic Organizations (LAOs) as part of the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). ETCTN LAOs will design, develop, monitor, conduct, and analyze early phase clinical trials (e.g., phase 0, phase 1, phase 2, pilot, and other experimental therapeutic clinical trials) involving agents under regulatory sponsorship for New Investigational Drug (IND) applications held by NCI's Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). Each ETCTN LAO will participate in clinical trials it leads as well as clinical trials led by other LAOs in the network.

This BRAIN Initiative Notice of Funding Opportunity (NOFO) is to support scaled reagent production and distribution facilities involving technologies to access brain cell types. Facilities for production and distribution of these reagents by a broad set of neuroscientists will be encouraged. This NOFO is part of the BRAIN Initiative Armamentarium for Brain Cell Access transformative project. Efforts will be supported to produce and distribute gene transfer, gene regulation, and genome engineering reagents for use in both genetically tractable and less tractable systems, including primates and human tissue, which are relevant for future translational efforts. Reagents to be produced and distributed are those designed and validated under other NOFOs from the Armamentarium transformative project.

The Division of Kidney, Urologic, and Hematologic Diseases (KUH) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) currently supports several institutional and individual training and career development programs. The purpose of this Notice of Funding Opportunity (NOFO) is to establish a single Coordinating Center to unite and harmonize these programs, which collectively aim to recruit, train, and retain an active, national community of researchers in KUH mission areas across career stages. This highly integrated community will be called KUH-FAMILY (Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning communitY).

This announcement (NOFO) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols.The NIH SIREN Network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies.Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA.

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for a new Clinical Trial Center (CTC) and up to seven Clinical Centers (CCs) for the HeartShare 2.0 program. The CTC will coordinate precision clinical trial activities focused on heart failure with preserved ejection fraction (HFpEF), including master protocol development, project management, recruitment oversight, performance milestones, and scientific conduct of trials. The CCs will recruit and retain heart failure patients and controls. The CCs will participate in all aspects of conducting a deep phenotyping protocol and longitudinal follow-up of HFpEF patients; obtaining tissue biopsies; and recruiting patients for future clinical trials.Eligible applicants may submit proposals for either the CTC or CC, but must have different PIs. Each application should include CTC or CC as part of their project title.Companion NOFO for RFA-HL-27-009 will support a Data Translation Center (DTC) for overall coordination of the HeartShare program.

This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invites an application from an eligible organization to apply. Please see Section III. Eligibility for additional information. The NHLBI is announcing its intent to issue a single source cooperative agreement to Northwestern University. This NOFO solicits a renewal of the Data Translation Center for an ongoing NHLBI phenomics program, HeartShare, to coordinate the overall project, continue to oversee enrollment of a cohort of patients with heart failure with preserved ejection fraction (HFpEF), curate and analyze prospective deep phenotyping data, and support planning, implementation, and data analysis for clinical trials. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.Companion NOFO RFA-HL-27-008 will support Clinical Centers for recruitment and follow-up of heart failure patients and a Clinical Trial Center for new clinical trial activities.

This Notice of Funding Opportunity (NOFO) solicits cooperative agreement research applications to support a multidisciplinary program titled "Accelerating Product Excellence in Innovation and for Clinical Adoption" (APEx), that will facilitate advancement of promising strategies and products for tissue engineering and regenerative medicine (TE/RM). APEx will be composed of Resource Centers (RCs) and associated Interdisciplinary Translational Projects (ITPs) in the area of therapeutics (including adult stem cell-based treatments), sensors, and diagnostics. RCs will capitalize on their available clinical, scientific, industrial, regulatory and commercialization expertise, to deliver technical support, research capacity, administrative infrastructure and regulatory and commercialization support to the ITPs and guide them to complete pre-clinical studies toward initiation of clinical trials. During this funding cycle, APEx will complete validation, manufacturing, and preclinical testing of the most promising products, which may include, but are not limited to products for detecting or treating tissue damage caused by congenital defect, traumatic injury, or chronic disease. Products that support early detection of chronic pathologies, monitoring of validated biomarkers of health or disease, as well as approaches to reduce or prevent resulting damage, are especially encouraged. The outcome of APEx will be TE/RM products with their regulatory approvals in place for first-in-human studies, along with associated clinical study protocols, and synthesis and manufacturing protocols rea...

This notice of funding opportunity (NOFO) encourages applications for investigator-initiated multi site clinical trials (e.g., efficacy, effectiveness, or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions), and/or multicomponent interventions that include physical, psychological, and/or nutritional approaches in NCCIH- designated areas of high research priority. Clinical Coordinating Centers (CCC) should develop and implement the proposed fully powered multi-site clinical trial (Phase III and beyond). The objective of a CCC application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. CCC applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. CCC applications submitted under this NOFO will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center (DCC) application (U24), submitted under PAR-24-087 proposing a data analysis and data management plan for the clinical project is required. Both a CCC application and a corresponding DCC application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website: (h...